Holders — by stockHoldings — by fund
NEXTBio Capital Management LP
Everything this manager disclosed owning in US-listed stocks — its complete Form 13F portfolio · as of 2026-09-30 · filed with the SEC up to 45 days after quarter end · CIK 0002038158
$234.4M
disclosed book value
25
positions
13.2%
largest position share
Positions, as of 2026-09-30
top 25 of 25 · 13F covers long US-listed positions only — cash, bonds, private and foreign stakes are not disclosed · PUT/CALL tags = options positions (share-equivalents), not shares held
| # | Issuer | Shares | Value | % of book |
|---|---|---|---|---|
| 1 | PTGXPROTAGONIST THERAPEUTICS INC | 219,333 | $30.9M | 13.2% |
| 2 | STTKSHATTUCK LABS INC | 3.7M | $25.4M | 10.8% |
| 3 | CMPSCOMPASS PATHWAYS PLC | 1.8M | $22.1M | 9.4% |
| 4 | RYTMRHYTHM PHARMACEUTICALS INC | 131,758 | $12.5M | 5.4% |
| 5 | VORVOR BIOPHARMA INC | 620,931 | $11.8M | 5.1% |
| 6 | PHVSPHARVARIS N V | 372,552 | $11.8M | 5% |
| 7 | XENEXENON PHARMACEUTICALS INC | 310,225 | $11.5M | 4.9% |
| 8 | ZBIOZENAS BIOPHARMA INC | 426,736 | $11.5M | 4.9% |
| 9 | PVLAPALVELLA THERAPEUTICS INC NE | 80,409 | $11.1M | 4.7% |
| 10 | GPCRSTRUCTURE THERAPEUTICS INC | 312,496 | $9.8M | 4.2% |
| 11 | ORICORIC PHARMACEUTICALS INC | 684,476 | $9.2M | 3.9% |
| 12 | ENTXENTERA BIO LTD | 2.9M | $8.5M | 3.6% |
| 13 | VSTMVERASTEM INC | 906,742 | $7.3M | 3.1% |
| 14 | IVAINVENTIVA SA | 1.8M | $6.6M | 2.8% |
| 15 | ZLABZAI LAB LTD | 238,362 | $6.3M | 2.7% |
| 16 | PCVXVAXCYTE INC | 107,223 | $6.1M | 2.6% |
| 17 | COGTCOGENT BIOSCIENCES INC | 178,036 | $5.7M | 2.4% |
| 18 | KRSAKORSANA BIOSCIENCES INC | 175,403 | $5.6M | 2.4% |
| 19 | CBIOCRESCENT BIOPHARMA INC. | 372,856 | $5.4M | 2.3% |
| 20 | BLSMBLOSSOMHILL THERAPEUTICS INC | 250,000 | $4.7M | 2% |
| 21 | IRONDISC MEDICINE INC | 52,655 | $3.4M | 1.5% |
| 22 | LBRXLB PHARMACEUTICALS INC | 69,549 | $2.7M | 1.1% |
| 23 | ADRXADARX PHARMACEUTICALS INC | 100,000 | $2.0M | 0.9% |
| 24 | GLUEMONTE ROSA THERAPEUTICS INC | 111,455 | $1.3M | 0.6% |
| 25 | EVMNEVOMMUNE INC | 119,063 | $983,460 | 0.4% |
Source: SEC Form 13F-HR, reporting period 2026-09-30. Values are the manager's filed June-30-style quarter-end marks, not live prices. Research, not investment advice.